HOME
COMPANY
RESEARCH
NEWS & EVENTS
CONTACT US
中文
   

FUZIANS

   
 

NEWS

Fusians Biomedicals, Inc., has signed an exclusive license agreement with the University of Alabama at Birmingham Research Foundation to further develop their fusion inhibitors ...... more

 

 

 

Fuzians Biomedicals, Inc., is a world leader in pharmaceutical development industry. Fuzian is dedicated to innovative design of novel pharmaceuticals by combination of state-of-the-art biomedical and chemical technologies. The focus of Fuzian is viral diseases which are among the leading causes of death in the United States and the world. Currently there are a limited number of antiviral classes that target different mechanisms of virus replication. It has been recognized that the most effective treatment for viral   diseases is the combination therapy that simultaneously 

uses a variety of antiviral drugs to treat one particular viral disease, such as human immunodeficiency virus (HIV) infection. Scientists in Fuzians are developing novel classes of viral entry inhibitors (VEIs).